MedTrace Logo

The Effect of Forgiveness-based Motivational Interviewing

NCT07365943 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-26

No results posted yet for this study

Summary

This study aimed to examine the effect of forgiveness-based motivational interviewing on death anxiety, life satisfaction, and forgiveness disposition in patients with COPD. A randomized controlled experimental design with pretest, posttest, and one-month follow-up measurements was employed. The study sample consisted of 30 patients (experimental group: 15; control group: 15). The experimental group received forgiveness-based motivational interviewing, whereas no intervention was provided to the control group. Data were collected using a personal information form, the Death Anxiety Scale, the Life Satisfaction Scale, and the Forgiveness Scale. The findings revealed that, in the posttest and follow-up measurements, the experimental group had significantly lower mean scores on the Death Anxiety Scale compared to the control group (p\<0.05). Furthermore, the experimental group demonstrated significantly higher mean scores on the Life Satisfaction Scale and the Forgiveness Scale in the posttest and follow-up measurements than the control group (p\<0.05). This study concluded that forgiveness-based motivational interviewing effectively reduces death anxiety while enhancing life satisfaction and forgiveness disposition in patients with COPD. Therefore, implementing motivational interviewing for patients is recommended.

Conditions

  • Psychiatric Nursing
  • Psychoeducation
  • COPD (Chronic Obstructive Pulmonary Disease)
  • Forgiveness

Interventions

OTHER

forgiveness-based motivational interviewing

The forgiveness-based motivational interviewing was administered face-to-face, with each session lasting 40-60 minutes, scheduled twice a week over a three-week period (a total of six sessions).

OTHER

Control

no intervention was performed in the control group

Sponsors & Collaborators

  • Ömer USLU

    lead OTHER

Principal Investigators

  • Merve Şahin, PhD, RN · Bergama Necla Mithat Öztüre State Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-01
Primary Completion
2024-09-27
Completion
2024-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07365943 on ClinicalTrials.gov